Leading the Charge in Combatting Metastatic Cancer: Mestastop Raises $500K in Pre-Series A Round.
Mestastop Solutions, a pioneering player in the fight against cancer metastasis, has recently announced a significant milestone in its journey to combat one of the most deadly aspects of cancer. The company has raised Rs 4.5 crore (approximately $500,000) in a pre-Series A funding round led by the renowned investment firms 92 Angels and Malpani Ventures.
This latest funding round comes after Mestastop’s successful seed funding campaign in 2021, where the company secured Rs 2 crore with the backing of IIM Ahmedabad’s CIIE and support from IKP and a group of angel investors.
The newly acquired funds will play a pivotal role in advancing Mestastop’s mission to tackle cancer metastasis, a process that significantly reduces the chances of survival for cancer patients. Mestastop aims to generate essential proof-of-concept data by focusing on small molecules targeting specific metastasis-related factors. Additionally, these funds will support their ongoing efforts to repurpose existing drugs for metastasis prevention by identifying potential clinical candidates.
Mestastop is committed to utilizing the investment to develop new animal models and conduct clinical studies to bring innovative metastasis treatments to the market. The company will also focus on strategic business development activities to strengthen its position in the field.
Founded by Arnab Roy Chowdhury and Debabani Roy Chowdhury, Mestastop is making waves in cancer research by focusing on metastasis. They employ a unique approach, combining wet lab biology with predictive analytics to identify and distinguish the distinct properties of metastasis. These insights help to expedite drug discovery and enhance patient treatment options.
Malpani Ventures, a significant contributor to this funding round, has actively supported innovation in various domains. In addition to Mestastop, the investment firm has recently invested in other promising startups, such as Selligion Technologies, a cloud computing developer, and Nexxio, based in Bengaluru.
Mestastop’s dedication to advancing cancer research and treatment, particularly in metastasis, has garnered the support of investors and the medical community. With their latest funding injection, the company is poised to make significant strides in their mission to improve the lives of cancer patients and their families. The battle against metastatic cancer has a new ally, and the world is watching with great anticipation for the groundbreaking developments to come.
